Silo Pharma (SILO) shares fell 4.92% to $5.02 as QwikAgents joined AMD’s AI Developer Program. The move followed a sharp intraday decline from the $5.50 to $6.00 range before stabilization. The subsidiary gained access to development resources that support its platform expansion and testing activities.
Silo Pharma announced that its subsidiary QwikAgents entered AMD’s AI Developer Program to advance platform development. The program provides cloud access, development tools, training resources, and technical support for new projects. QwikAgents will use these resources to improve testing, optimization, and deployment processes.
The partnership focuses on expanding QwikAgents, a platform designed for automated digital agents across different workflows. The platform supports research, content creation, scheduling, coding, and browser automation tasks. The company aims to provide accessible tools for individuals, developers and businesses.
QwikAgents combines persistent memory, dedicated infrastructure, model routing, and encrypted backups within its platform. The system allows users to create and manage automated agents for various operational needs. The company expects improved performance through AMD’s development environment and resources.
QwikAgents continues developing a platform that enables users to deploy customized digital agents. The service includes options for personal use, developer projects, and business applications. Furthermore, the platform offers deployment features designed for different workload requirements.
The subsidiary plans to use AMD resources for hosting, benchmarking, training, and platform improvements. These activities will help QwikAgents evaluate performance and increase operational efficiency. Additionally, the company expects the program access to support future platform expansion.
Silo Pharma operates as a developmental-stage biopharmaceutical company focused on medical research programs. Its portfolio includes treatments targeting stress-related disorders, chronic pain, and central nervous system conditions. However, the company has also expanded into technology through its QwikAgents subsidiary.
Silo Pharma’s stock decline came despite the announcement of the AMD program participation. The shares moved lower after reaching higher intraday levels before settling near $5.02. Therefore, the market reaction reflected short-term price movement after the announcement.
The company continues advancing programs such as SPC-15 for post-traumatic stress disorder. It also develops SP-26 for fibromyalgia and chronic pain conditions. Silo Pharma maintains a preclinical program focused on Alzheimer’s disease research.
QwikAgents represents Silo Pharma’s expansion into automated technology solutions alongside its healthcare focus. The subsidiary targets users seeking flexible tools for workflow automation and digital operations. Hence, the AMD program supports ongoing development efforts for its technology platform.
The post Silo Pharma, Inc. (SILO) Stock: Slide 4.92% as QwikAgents Joins AMD AI Developer Program appeared first on CoinCentral.
